NCT04927169 - InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

March 30, 2022

Conditions

COVID-19Lymphocytopenia

Interventions

DRUG

Interleukin-7

IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

DRUG

PLACEBO

IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay

Trial Locations (6)

14051

Hospital Das Clinicas de Ribeirao Preto, Monte Alegre

18618

Upeclin-Unesp, Botucatu

88103

Hospital Sao Jose, São José

90035

Hospital de Clinicas de Porto Alegre, Porto Alegre

04021

Universidade Federal de Sao Paolo, São Paulo

04038

Hospital Edmundo Vasconcelos, Vila Clementino